WENZHOU, China, Aug. 12, 2025 /PRNewswire/ -- Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board.
View detailsVivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.
View detailsVivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis
View detailsTEL AVIV, Israel and SHANGHAI, Jan. 6, 2023 -- VivaVision, a pharmaceutical company developing innovative therapies for ocular diseases, and Everads Therapy, a biotech company developing optimized retinal therapies by leveraging its novel suprachoroidal
View detailsVivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator,
View detailsVVN001 demonstrating clinical and statistical superiority over vehicle in reducing total and sub-regional Corneal Fluorescein Staining scores
View details
Address ：Room 4020, Building B, Gene Medicine Valley North District, Ouhai District, Wenzhou City, Zhejiang Province
Mailbox：support@vivavisionbio.com
Copyright2020 VivaVision Biotech, Limited.
Record No ：Huicp no.18035530
